U.S. scientists say the cancer-fighting drug Gleevec -- remarkably successful in treating leukemia -- can lead to heart failure in some patients.
Researchers who conducted the study recommend patients taking Gleevec be monitored for heart-failure symptoms, The Wall Street Journal reported Monday, noting the scientists also urge similar drugs in development be tested for evidence for heart toxicity.
Gleevec is a targeted therapy, designed to attack only cancerous cells, while avoiding tissue damage in the rest of the body.
Dr. Jean-Bernard Durand, a cardiologist at the M.D. Anderson Cancer Center in Houston and an author of the study told The Journal that unlike chemotherapy, "The idea was that (targeted therapies) would limit collateral damage, when in fact we're finding that other tissues can be affected by this model."
Novartis AG, which manufactures Gleevec, said clinical trials and other studies have shown the incidence of heart failure involving Gleevec is "extremely rare."
The study appears in the journal Nature Medicine.
Copyright 2006 by United Press International
Related stories:
Activation of LYN kinase is associated with imatinib-resistance in CML patients
Activation of LYN kinase is associated with resistance to imatinib (Gleevec) in patients with chronic myelogenous leukemia (CML), researchers report in the June 24 online issue of the
Journal of the National Cancer Institute.
MicroRNA controls expression of oncogenes
A new study demonstrates that microRNAs can modulate the expression of well known tumor-specific oncogenic translocation proteins and may play a significant role in some human cancers. The research, published by Cell Press in the June issue of the journal
Cancer Cell, is likely to lead to new strategies for treating some specific lymphomas and leukemias.
Combination of 2 novel anti-cancer agents may help fight CML resistant to current therapy
Virginia Commonwealth University Massey Cancer Center researchers have identified that a combination of novel anti-cancer compounds is able to kill chronic myelogenous leukemia cells previously resistant to conventional forms of therapy.
Researchers find roadmap to next-generation cancer therapies
Pinpointing new targets for cancer treatments is as difficult as finding a needle in a haystack, yet a University of Rochester team has discovered an entire novel class of genes they believe will lead to a greater understanding of cancer cell function and the next generation of effective and less harmful therapies for patients.
Novel enzyme inhibitor paves way for new cancer drug
Combining natural organic atoms with metal complexes, scientists at The Wistar Institute have developed a new type of enzyme inhibitor capable of blocking a biochemical pathway that plays a key role in cancer development.
Immune system pathway identified to fight allergens, asthma
For the first time, researchers from the University of Pittsburgh School of Medicine have identified genetic components of dendritic cells that are key to asthma and allergy-related immune response malfunction. Targeting these elements could result in more effective drugs to treat allergic disorders and asthma, according to a study reported in the May edition of the journal
Nature Medicine.
Researchers discover a method for clamping down on a cancer-promoting enzyme
There are many pathways that allow an errant gene to turn a cell cancerous, and a number of these pathways go through a single enzyme called the p21-activated kinase 1, or PAK1.
Report describes first targeted therapy to produce remission of metastatic melanoma
In a demonstration that even some of the most hard-to-treat tumors may one day succumb to therapies aimed at molecular "weak points," researchers at Dana-Farber Cancer Institute report the first instance in which metastatic melanoma has been driven into remission by a targeted therapy.